Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Here’s What Happened

Fresenius SE & Co. (OTCMKTS:FSNUY) gapped up prior to trading on Wednesday. The stock had previously closed at $12.62, but opened at $13.44. Fresenius SE & Co. shares last traded at $12.8090, with a volume of 14,732 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

The stock has a market cap of $28.84 billion, a price-to-earnings ratio of 16.21 and a beta of 0.62. The stock’s 50 day moving average price is $13.18 and its two-hundred day moving average price is $12.41. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. The business had revenue of $6.91 billion for the quarter, compared to analyst estimates of $6.65 billion. Equities research analysts forecast that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.